Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8486975	MSD MERCK CO	Non-nucleoside reverse transcriptase inhibitors	Oct, 2031 (9 years from now)
CN102971308A	MSD MERCK CO	Non-Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)
CN102971308B	MSD MERCK CO	Non-Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)
IN201208211P4	MSD MERCK CO	Non Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)
IN311693B	MSD MERCK CO	Non-Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)
EP2552902B1	MSD MERCK CO	Non-Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)
EP2552902A1	MSD MERCK CO	Non-Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)
EP2924034A1	MSD MERCK CO	Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor	Mar, 2031 (8 years from now)
EP2924034B1	MSD MERCK CO	Pharmaceutical Composition Comprising A Non-Nucleoside Reverse Transcriptase Inhibitor	Mar, 2031 (8 years from now)
EP2552902A4	MSD MERCK CO	Non-Nucleoside Reverse Transcriptase Inhibitors	Mar, 2031 (8 years from now)

Drugs and Companies using DORAVIRINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.